The Pandemic H30 Subclone of Sequence Type 131 (ST131) as the Leading Cause of Multidrug-Resistant Escherichia coli Infections in the United States (2011–2012)

Johnson, James R.; Porter, Stephen; Thuras, Paul; Castanheira, Mariana

doi:10.1093/ofid/ofx089

Cited by 120 publications

(131 citation statements)

References 40 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…bla CTX-M+TEM was the dominant bla gene type, which is consistent with the results of other studies detecting these genes in ESBL producers from companion animals in China and other counties [11,16,31]. CTX-M-15-producing E. coli of ST131 was not found in the present study, which is regarded as an emerging human pandemic clone [32]. However, ESBL-producing E. coli has been detected in urinary samples of dogs in Europe [12].…”

Section: Discussionsupporting

confidence: 91%

Characterization of ESBL-producing Escherichia coli recovered from companion dogs in Tai'an, China

Liu

Zhou³

et al. 2017

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Animals are considered to be reservoirs of extended-spectrum beta-lactamase (ESBL)-producing bacteria, but few epidemiological data on ESBL-producing Escherichia coli urinary tract isolates in pet dogs are available in China. Methodology: This study was conducted to describe the prevalence and characterization of ESBL producers among E. coli urinary tract isolates from pet dogs in Tai'an, China. Results: A total of 118 E. coli were obtained from urinary samples of 80 companion dogs suffering from acute or chronic cystitis, of which three isolates from different dogs were ESBL producers. One isolate from dog A was of phylogroup A/ST410/CTX-M-15/TEM-1; one from dog B was of phylogroup B1/ST533/CTX-M-15/TEM-1; one from dog C was of phylogroup D/ST648/CTX-M-15. All ESBL producers were resistant to ampicillin, cephalexin, cefalotin, cefpodoxime, ceftiofur, enrofloxacin, marbofloxacin, and trimethoprim/sulfamethoxazole, but were susceptible to imipenem and amoxicillin/clavulanic acid. E. coli of ST533 carrying blaCTX-M-15 were first detected in pet dogs in China. Conclusions: Collectively, the findings could expand our knowledge about the prevalence and characterization of ESBL-producing E. coli urinary tract isolates in pet dogs in China.

show abstract

Section: Discussionsupporting

confidence: 91%

Characterization of ESBL-producing Escherichia coli recovered from companion dogs in Tai'an, China

Liu

Zhou³

et al. 2017

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…Avoidance of repeated antimicrobial use, which may select for MDR bacterial strains, is desirable because of the potential risk posed to the individual and in-contact humans and animals. Further intensifying concern is the isolation of successful human-associated clonal lineages including ST131-B2 from the urine of dogs (Pomba et al, 2009;Platell et al, 2010), as such strains have been reported in association with extraintestinal disease in both humans and animals (Nicolas-Chanoine et al, 2008;Blanco et al, 2009;Oteo et al, 2009;Ewers et al, 2010;Johnson et al, 2010;Lee et al, 2010;Blanco et al, 2011;Platell et al, 2011a, c;Rogers et al, 2011;Nebbia et al, 2014;Madigan et al, 2015).…”

Section: Discussionmentioning

confidence: 99%

Preventing canine urinary tract infection (UTI) using an asymptomatic bacteriuria (ASB) Escherichia coli strain

Thompson¹

View full text Add to dashboard Cite

Bacterial cystitis occurs with reasonable frequency in dogs. Persistent infection and repeated reinfection (recurrent bacterial urinary tract infection, hereafter termed recurrent UTI) is reported less frequently. Recurrent urinary tract infection is predominantly diagnosed in dogs with a predisposing or comorbid condition, and episodes are often subclinical. Escherichia coli is the most frequently cultured species in both uncomplicated bacterial cystitis and recurrent UTI.Antimicrobial therapy limitations and global emergence of bacterial strains that are both virulent and multidrug-resistant (MDR) has led to an urgent requirement for novel control strategies in both companion animals and humans. Escherichia coli strain 83972 has been successfully used to colonise the bladder of humans with recurrent UTI in order to reduce the incidence of subsequent febrile UTI via the process of active bacterial interference. This strategy has not been utilised in dogs to date but may prove an effective alternative to antimicrobial therapy if it can be shown to colonise the bladder of dogs safely and effectively compete with uropathogens.A retrospective study to examine the signalment, infecting strains, presence of clinical signs, and incidence of pyuria in Australian dogs with recurrent urinary tract infection was performed. The findings were similar to those of two large North-American studies with regard to signalment, predisposing or comorbid diseases, bacterial species isolated, and resistance to commonly used oral antimicrobials, although the median age of our dogs was higher at 10 years (7 years in both prior studies). Examination of the E. coli isolates from a subset of nine dogs provided new information on phylogenetic group, virulence gene profiles, haemolytic phenotype, expression of type 1 fimbriae, and sequence type (ST). Phylogenetic groups F and B2 were frequently identified, representing 13/32 (41%) and 8/32 (25%) of isolates respectively, but no phylogroup B2 isolates were MDR, in comparison with phylogroup F isolates, which accounted for 12/16 (75%) MDR isolates. Clonal groups of global importance such as ST131-B2, ST354-F, ST38-D and ST457-F were represented, with possible implications for both companion animal and human health. Of particular concern was the repeated isolation of ST354-F strains from the urine of a paralysed dog over a 3-year period.When competition experiments between E. coli 83972 and a selection of canine uropathogenic E. coli (UPEC), including emerging, highly virulent MDR strains with zoonotic potential, were performed in pooled canine urine, E. coli 83972 was largely non-competitive against the canine isolates after 17 hr of incubation. This finding contrasted with the competitive superiority previously exhibited by E. coli 83972 in pooled human urine in competition experiments with human UPEC strains. In 5/10 trials, the E. coli 83972 was not outcompeted in canine urine, iii however, and given that the starting ratio in dogs following prophylactic bladder colonisation would ...

show abstract

“…Common scenarios for evacuation such as road trauma & combat injuries have high background rates of secondary infection [117].…”

Section: Patientsmentioning

confidence: 99%

“…High rates of infection caused by multi-resistant gram-negative bacilli have been reported in injured military personnel evacuated from Iraq and Afghanistan [114,115]. Some studies estimate bacterial infection complicating 15 to 25% of admissions [116,117]. Etiological investigation of infections has implicated both environmental contamination of field hospitals and frequent nosocomial transmission within the military health system [118,119].…”

Section: Aeromedical Evacuation Of Military Personnelmentioning

confidence: 99%

See 1 more Smart Citation

Antimicrobial resistant Escherichia coli. Clinical, epidemiological and molecular characteristics in the Australian region

Rogers¹

View full text Add to dashboard Cite

BackgroundEscherichia coli is the most common gram-negative bacteria to cause human infection. The pathological manifestations range from minor disease to severe life threatening sepsis. Urinary tract infection, most often caused by E. coli, is also the most common bacterial infection in humans. Since the inception of antimicrobial therapy in the early 20 th century, E. coli has systematically developed resistance to almost all known antimicrobials, posing a challenge for the treatment of such infections.From a global perspective, the first decade of the 21 st century heralded a change in the epidemiology and tempo of resistance amongst E. coli. Previously, resistance to third generation cephalosporins (3GC) was primarily associated with current or previous healthcare exposure. In the past decade however, expandedspectrum cephalosporin resistant E. coli (ESC-R-EC), usually mediated by Extended Spectrum betalactamase (ESBL) genes has spread widely within the communities of many regions, independent of healthcare associated acquisition.The latter half of this decade has led to the delineation of two further challenges amongst resistant E. coli.The first is the identification of Sequence Type 131 E. coli (ST131), a global 'pandemic' clone fine-tuned for resistance and virulence. This clone is now implicated in a significant proportion of community ESBL E. coli infections globally. The second challenge is the emergence of E. coli harbouring carbapenemase genes, conferring resistance to carbapenem antimicrobials used to treat severe ESBL producing E. coli infection. MethodsThrough several studies we have aimed to better define global and local aspects of antimicrobial resistant E.coli, in particular ESC-R-EC. The studies have included clinical and laboratory based research. Clinical research included a multi-centre case-control study of community onset ESC-R-EC infection inAustralia and New Zealand, and a national survey of health services' infection control practices pertaining to multi-resistant gram-negative bacilli and patients at risk of harbouring these.Laboratory research included molecular epidemiological investigation of E. coli from two sources. The first was isolates from the 182 participants in the case-control study, comprising a broad sample of community onset 3GC resistant and susceptible E. coli from Australia and New Zealand. The second was a collection of isolates from a previously conducted study on carriage of resistant E. coli in overseas travellers returning to Australia.Results 182 patients (91 cases and 91 controls) were recruited across six tertiary hospitals in Australia andNew Zealand for the case-control study. Multivariate logistic regression identified risk factors for 3GCR-EC III including birth on the Indian subcontinent (OR=11. 13, 2.17-56.98, p=0.003) being of the recently defined fimH 30 sub-clone variant. Whilst patients with ST131 were significantly more likely to have an upper rather than lower urinary tract infection (relative risk 1.8, p=0.040), they were otherwise rel...

show abstract

The Pandemic H30 Subclone of Sequence Type 131 (ST131) as the Leading Cause of Multidrug-Resistant Escherichia coli Infections in the United States (2011–2012)

Cited by 120 publications

References 40 publications

Characterization of ESBL-producing Escherichia coli recovered from companion dogs in Tai'an, China

Characterization of ESBL-producing Escherichia coli recovered from companion dogs in Tai'an, China

Preventing canine urinary tract infection (UTI) using an asymptomatic bacteriuria (ASB) Escherichia coli strain

Antimicrobial resistant Escherichia coli. Clinical, epidemiological and molecular characteristics in the Australian region

Contact Info

Product

Resources

About